Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis.
Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis / Guglielmelli, Paola; Barosi, Giovanni; Rambaldi, Alessandro; Marchioli, Roberto; Masciulli, Arianna; Tozzi, Lorenzo; Biamonte, Flavia; Bartalucci, Niccolò; Gattoni, Elisabetta; Lupo, Maria Letizia; Finazzi, Guido; Pancrazzi, Alessandro; Antonioli, Elisabetta; Susini, Maria Chiara; Pieri, Lisa; Malevolti, Elisa; Usala, Emilio; Occhini, Ubaldo; Grossi, Alberto; Caglio, Silvia; Paratore, Simona; Bosi, Alberto; Barbui, Tiziano; Vannucchi, Alessandro M. - In: BLOOD. - ISSN 0006-4971. - STAMPA. - 118:(2011), pp. 2069-2076. [10.1182/blood-2011-01-330563]
Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis
GUGLIELMELLI, PAOLA;TOZZI, LORENZO;BIAMONTE, FLAVIA;BARTALUCCI, NICCOLO';PANCRAZZI, ALESSANDRO;ANTONIOLI, ELISABETTA;SUSINI, MARIA CHIARA;PIERI, LISA;MALEVOLTI, ELISA;BOSI, ALBERTO;VANNUCCHI, ALESSANDRO MARIA
2011
Abstract
Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis.
| File | Dimensione | Formato | |
|---|---|---|---|
|
GuglielmelliBLOOD_RAD001.full.pdf
Accesso chiuso
Descrizione: Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis
Tipologia:
Pdf editoriale (Version of record)
Licenza:
Tutti i diritti riservati
Dimensione
317.3 kB
Formato
Adobe PDF
|
317.3 kB | Adobe PDF | Richiedi una copia |
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
